AstraZeneca PLC (AZN)
NASDAQ: AZN · IEX Real-Time Price · USD
78.13
-0.39 (-0.50%)
At close: Jul 26, 2024, 4:00 PM
78.90
+0.77 (0.99%)
After-hours: Jul 26, 2024, 7:59 PM EDT
AstraZeneca Revenue
AstraZeneca had revenue of $12.94B in the quarter ending June 30, 2024, with 13.33% growth. This brings the company's revenue in the last twelve months to $49.13B, up 10.45% year-over-year. In the year 2023, AstraZeneca had annual revenue of $45.81B with 3.29% growth.
Revenue (ttm)
$49.13B
Revenue Growth
+10.45%
P/S Ratio
4.93
Revenue / Employee
$546,529
Employees
89,900
Market Cap
242.25B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 45.81B | 1.46B | 3.29% |
Dec 31, 2022 | 44.35B | 6.93B | 18.53% |
Dec 31, 2021 | 37.42B | 10.80B | 40.58% |
Dec 31, 2020 | 26.62B | 2.23B | 9.16% |
Dec 31, 2019 | 24.38B | 2.29B | 10.38% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 379.49B |
Johnson & Johnson | 78.71B |
Merck & Co. | 61.40B |
AbbVie | 54.40B |
Novartis AG | 48.86B |
Thermo Fisher | 42.49B |
Abbott Laboratories | 40.33B |
Novo Nordisk | 35.35B |
AZN News
- 9 hours ago - Europe's Markets Are Cheap. 4 Stocks to Play. - Barrons
- 1 day ago - Govt body's procedures means people with cancer aren't getting drug - AstraZeneca boss - Skynews
- 1 day ago - AstraZeneca Posts Earnings Beat, Lifts Guidance on Strong Sales - Investopedia
- 1 day ago - AstraZeneca's H1 and Q2 2024 Financial Results - Business Wire
- 1 day ago - AstraZeneca lifts full-year outlook on upbeat demand for therapies - Reuters
- 8 days ago - These Stocks Offer Gains Without the U.S. Political Drama - Barrons
- 11 days ago - AstraZeneca Closes Acquisition of Amolyt Pharma - GlobeNewsWire
- 25 days ago - AstraZeneca's COVID prevention drug application gets EU fast-track assessment - Reuters